Current Pharmaceutical Biotechnology, an important international scientific journal, dedicates volume 12 number 2 of February 2011 to the topic of reprogramming of normal and cancer stem cells [Reprogramming of normal and cancer stem cells].
The volume is edited by Pier Mario Biava, medical researcher, whose pioneering research has opened a new way of dealing with cancer that in recent years has been recognized as valid and innovative from the international scientific community.
Thousands of researches that in recent years all over the world have demonstrated the assumption supported by Biava since the beginning and that is that the malignancy of the tumor is linked to the presence of mutated stem cells , responsible for relapses of the disease and metastases.
Studies have shown that these cells, which respond poorly to chemo and radiotherapy, can be reprogrammed / normalized, confirming the properties in this sense of some substances already identified by Biava himself and which, in the studies involving patients considered not otherwise treatable, have given very valid results, including the total disappearance of the tumor disease, objectively highlighted with the most advanced clinical methods.
Hence the special issue of Current Pharmaceutical Biotechnology which collects articles by numerous scholars working in prestigious international scientific institutions: Tokyo Cancer Center, prestigious American, Indian, Indonesian universities and research centers, important Italian universities, such as the University of Milan , of Rome “La Sapienza”, of Pisa, L’Aquila, Varese, (Bocconi for statistics) as well as of prestigious Institutes of Hospitalization and Scientific Care, such as Humanitas and Multimedica of Milan.
The special issue consists of 15 articles, of which 3 written by Biava with various collaborators.
The article which sees the participation with Bocconi and the University of L’Aquila aims to improve the therapeutic intervention, suggesting to doctors precise treatment protocols with differentiation factors of stem cells.
The article that sees the participation with the University La Sapienza is important because it describes the strengthening action in slowing the growth of colon cancer due to the simultaneous administration of some chemotherapeutic agents such as uracil 5 fluoride and stem cell differentiation factors: this fact is extremely important, because it shows the possibility of integrating traditional therapies with consolidated efficacy and new modulation and differentiation therapies.
From the therapeutic point of view, the article signed as first author by Tito Livraghi, the father of percutaneous treatment of liver tumors, written in collaboration with clinicians of the ‘University of Milan, which describes the cases of complete regression in patients with intermediate-advanced hepatocarcinoma, treated with the differentiation factors developed by Biava.
The complete regression cases concern 13% one in 7 of patients already given for terminals, while considering the patients who have obtained a partial regression and a stabilization of the disease the percentage rises up to 36% or one in 3.
Very relevant results if we consider that no treatment, (with the exception of surgery or transplantation in the limited cases where they are possible), still shows similar survival results after years of patients already evaluated as terminal.
These data, objectively verified and widely documented in the issue of the journal, show that it is necessary to start even more extensive studies on these therapies for two reasons: to offer sufferers new possibilities of cure, without invalidating or rather enhancing the therapies already in use, and to continue to increase survival rates.